I appreciate the question, though I should clarify upfront--I'm not a medical expert, but as Executive Director of LifeSTEPS serving over 100,000 low-income residents in affordable housing across California, I've seen how prescription costs devastate families, especially seniors on Medicare. We work with thousands of seniors aging in place, and the Part D "donut hole" still crushes people even after improvements. I've watched residents choose between their heart failure medication and groceries because their copays jump from $47 to $400+ once they hit that coverage gap mid-year. One of our service coordinators helped a 72-year-old veteran who was splitting his Entresto doses in half to make them last longer--incredibly dangerous, but he literally couldn't afford the $380 monthly cost during his gap period. What actually works: our teams connect residents to manufacturer patient assistance programs (Novartis has one specifically for Entresto that can reduce costs to $10/month for qualifying patients), Medicare Extra Help for prescription costs, and state pharmaceutical assistance programs. We achieved a 98.3% housing retention rate in 2020 partly because we caught these medication cost crises before people had to choose between pills and rent. The brutal reality is that specialty medications like Entresto hit our most vulnerable populations hardest--people managing multiple chronic conditions who can least afford to skip doses. I've seen too many hospital readmissions that could've been prevented if the medication was simply affordable in the first place.
1. Entresto (sacubitril/valsartan) is a medication for heart failure that reduces hospitalization and improves survival by enhancing natriuretic peptide effects and blocking angiotensin II. Entresto is costly at around $600-$700 per month retail price because it's a branded drug with patent protection, high research and development costs, and limited generic options. Out-of-pocket cost depends on formulary tier, deductible status, pharmacy pricing, and eligibility for copay or patient-assistance programs. 2. Most Medicare Part D and Medicare Advantage drug plans cover Entresto. Typical annual out-of-pocket cost for beneficiaries average around $300-$400, though this varies by plan and coverage stage. Entresto is not covered under Original Medicare Parts A and B unless the drug is administered in a hospital. 3. To reduce cost on Medicare review your Part D formulary and request a tier exception if Entresto is listed as non-preferred. You can use manufacturer support programs or foundations for copay help, although some eligibility rules apply. I encourage comparing Medicare plans annually since drug tiers differ widely. Using preferred pharmacies can lower coinsurance. Track deductible and coverage-gap phases to anticipate changes in copay. Lastly, watch for future generic versions or negotiated Medicare prices under the Inflation Reduction Act. 4. Many people with chronic heart failure report better breathing, fewer hospitalizations, and more energy after starting treatment with Entresto. Patients highlight the emotional relief of improved stability and better health options, but note the need for consistent dosing, lab checks, and coordination with other heart medications. 5. Entresto is one of the first drugs selected for Medicare price negotiation which may help lower drug costs in coming years. While not a cure, it's a cornerstone therapy that can greatly improve quality of life when used as part of a comprehensive heart-failure plan.
While there are the basic ways in reducing costs for Entresto that are common, maybe the best way for a medicare recipient to lessen the expense is to apply for manufacturer assistance programs while waiting for a generic version to come on line. Like for many medications, there are low income government subsidy programs that are available for Entresto, but like many of these programs that are operated by the government, they can often be slow and cumbersome. Norvatis, the company that manufactures Entresto does offer patient assistance programs that are not so bogged down by red-tape and can offer a viable alternative to government programs. In addition, there is some evidence that there will be generics of this medication that will soon hit the market. So while you are waiting for the generic alternatives, those on Medicare may want to look into manufacturer discounts for Entresto as their best way of reducing costs.
Entresto is expensive because it's a brand-name medication without a generic version available, meaning that Novartis can price the drug as they see fit, especially after years of research, clinical testing, and production costs. Its high list price also reflects the complex way drug prices are set in the U.S. which is usually through negotiations among drugmakers, insurers, and pharmacy benefit managers. Entresto was selected for Medicare's first round of drug price negotiations, with lower maximum fair prices expected in 2026, showing how significant the cost impact of this drug is. For patients, what you actually pay out of pocket depends on your Medicare plan's formulary tier, deductible, pharmacy choice, and whether you've reached your annual spending cap provided by insurance. Most Medicare Part D and Medicare Advantage plans do cover Entresto, but copays can vary. To lower costs, I recommend that patients review their plan options during open enrollment to find one that lists Entresto on a preferred tier or offers lower copays at in-network pharmacies. Starting in 2025, Medicare has introduced a $2,000 annual cap on out-of -pocket costs for prescriptions along with the option to spread payments over the year, which could be helpful for patients that need more expensive drugs. Low-income beneficiaries may also qualify for the Extra Help program, which can significantly cut costs of copays and premiums. Patients can also ask their doctor to request a tiering exception if Entresto is on a high-cost tier, or explore manufacturer assistance through the Novartis Patient Assistance Foundation. Many patients report meaningful improvements on Entresto, including more energy, fewer symptoms of heart failure, and better quality of life. Some patients report side effects including mild dizziness or cough that usually subsides with monitoring. Overall, Entresto offers life-changing benefits for many with heart failure, and with Medicare reforms and smart insurance plan choices the cost burden can become more manageable.
1. Entresto is historically expensive because it was noted to be one of the pillars that reduced heart failure readmissions but more importantly dramatically improved heart function. It has also now been recommended as guideline directed therapy for anyone with Heart Failure with a low ejection fraction A few factors may be insurance, co-pay, out of pocket deductible. 2. Medicare does cover Entresto however, accurate documentation must be provided. I have multiple patients on Entresto but the patient story that sticks out to me is regarding a middle age patient of mine with heart failure from unknown causes. His heart function was low (~ 17% - normal is 60-65%.) We started him on entresto however, his insurance quickly became an issue with coverage. With sending the prescription to Canada he was able to receive the medication and subsequently improve his heart function to 60%. He continues to receive his Canadian Rx and does extremely well. Entresto samples can also help with coverage. We have been able to appeal some insurance companies once we demonstrate the significant improvement in heart function and patient's symptoms.
Entresto can be life-changing for many of my heart failure patients, but I've seen how its cost often creates real barriers to care. Even with Medicare, patients may face out-of-pocket costs that vary widely based on their specific plan and whether they've met their deductible. The medication's high price is largely due to research and development costs, brand exclusivity, and limited generic alternatives. I've had patients on fixed incomes hesitate to refill their prescriptions, forcing us to make difficult choices about balancing affordability with optimal heart care. In my practice, I've helped patients lower their costs by exploring Medicare Part D plan comparisons annually—small changes in coverage tiers can lead to big savings. Some patients qualify for extra help through programs like "Low-Income Subsidy" or manufacturer assistance from Novartis. I recall one patient who reduced his monthly cost from over $100 to under $20 by enrolling in such a program. For those struggling financially, I encourage talking to their cardiologist and pharmacist about all options before discontinuing the medication—stopping Entresto abruptly can worsen heart failure symptoms. Practical, proactive planning can make essential treatments like Entresto accessible without overwhelming financial stress.